VLNC Messages for Smoking
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to learn how a messaging campaign about reduced nicotine cigarettes and policy, combined with the use of very low nicotine cigarettes (VLNCs), affects smoking behavior and attitudes among adult smokers. The study also aims to assess the efficacy of the messages in different populations, including smokers with past-month serious psychological distress (SPD), low socioeconomic status (SES), and those in neither category. The primary hypothesis is: exposure to messages in combination with VLNC use will lead to less cigarettes use compared to VLNCs without messages. Researchers will compare: The effects of receiving VLNCs with messages (treatment group) to receiving VLNCs without messages (control group). Participants will: Complete a baseline survey and be randomly assigned to one of two groups: treatment (VLNCs + messages) or control (VLNCs only). Attend weekly study visits for surveys, breath samples, and receive supply of VLNCs , either with or without the messaging campaign. Complete brief daily surveys through text messages.
Research Team
Eligibility Criteria
This trial is for adult smokers, including those with recent serious psychological distress or low socioeconomic status. Participants must be willing to attend weekly study visits and complete daily surveys via text message.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Control message (Behavioral Intervention)
- VLNC messages (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Georgia State University
Lead Sponsor
Dr. Jian-Dong Li
Georgia State University
Chief Executive Officer since 2011
PhD in Biomedical Sciences from University of California, San Francisco; MD from Qingdao University School of Medicine
Dr. Steve Simonson
Georgia State University
Chief Medical Officer since 2014
MD from Medical College of Wisconsin; Master's in Health Sciences from Duke University School of Medicine
University of South Carolina
Collaborator
Hippokratis Kiaris
University of South Carolina
Chief Executive Officer since 2021
PhD in Molecular Biology
Marjorie Jenkins
University of South Carolina
Chief Medical Officer since 2023
MD
Emory University
Collaborator
Dr. R. Donald Harvey
Emory University
Chief Medical Officer
MD from Emory University School of Medicine
Dr. George Painter
Emory University
Chief Executive Officer since 2013
PhD in Synthetic Organic Chemistry from Emory University
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School